Trial reportPloS one2014
Characterization of lung function impairment in adults with bronchiectasis.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis
Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis (HYBRID): A Randomized, Multi-center, Double-blind, Parallel-group Study
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Inhaled corticosteroids for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- Pulmonary function and airflow limitation in bronchiectasis: a case-control study of two independent cohorts.BMJ open respiratory research · 2026Article
- Evaluating serum TNF α in relation to bronchiectasis severity: Insights from FACED and BSI scoring systems.Lung India : official organ of Indian Chest Society · 2026Article
- Clinical Impacts ofJournal of clinical medicine · 2024Article
- Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Bronchiectasis in Asia: a review of current status and challenges.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- COPD Assessment Test and risk of readmission in patients with bronchiectasis: a prospective cohort study.ERJ open research · 2024Article
- Diffusing capacity as an independent predictor of acute exacerbations in chronic obstructive pulmonary disease.Scientific reports · 2024Article
- Bacteria and viruses and clinical outcomes of asthma-bronchiectasis overlap syndrome: A cohort study.Clinical and translational allergy · 2024Article
- Endobronchial optical coherence tomography or computed tomography for evaluating progression of bronchiectasis.ERJ open research · 2023Article
- Effects of Probiotics on Clinical Manifestations of Bronchiectasis: A Randomized, Triple Blinded, Placebo-Controlled Clinical Trial.Tanaffos · 2023Article
- Article
- Clinical characteristics, radiological features, and disease severity of bronchiectasis according to the spirometric pattern.Scientific reports · 2022Article
- Research advances and clinical management of bronchiectasis: Chinese perspective.ERJ open research · 2022Review
- Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis.Canadian respiratory journal · 2022Article
- Telemedicine and Remote Monitoring as an Adjunct to Medical Management of Bronchiectasis.Life (Basel, Switzerland) · 2021Review
- ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group.ERJ open research · 2021Article
- Decreased ventilatory efficiency during incremental exercise in bronchiectasis.Journal of thoracic disease · 2020Article
- The biology of pulmonary exacerbations in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Next-generation sequencing for identifying genetic mutations in adults with bronchiectasis.Journal of thoracic disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCharacteristics of lung function impairment in bronchiectasis is not fully understood.
objectivesTo determine the factors associated with lung function impairment and to compare changes in spirometry during bronchiectasis exacerbation and convalescence (1 week following 14-day antibiotic therapy).
methodsWe recruited 142 patients with steady-state bronchiectasis, of whom 44 with acute exacerbations in the follow-up were included in subgroup analyses. Baseline measurements consisted of chest high-resolution computed tomography (HRCT), sputum volume, purulence and bacteriology, spirometry and diffusing capacity. Spirometry, but not diffusing capacity, was examined during acute exacerbations and convalescence.
resultsIn the final multivariate models, having bronchiectasis symptoms for 10 years or greater (OR = 4.75, 95%CI: 1.46-15.43, P = 0.01), sputum culture positive for Pseudomonas aeruginosa (OR = 4.93, 95%CI: 1.52-15.94, P<0.01) and HRCT total score being 12 or greater (OR = 7.77, 95%CI: 3.21-18.79, P<0.01) were the major variables associated with FEV1 being 50%pred or less; and the only variable associated with reduced DLCO was 4 or more bronchiectatic lobes (OR = 5.91, 95%CI: 2.20-17.23, P<0.01). Overall differences in FVC and FEV1 during exacerbations and convalescence were significant (P<0.05), whereas changes in other spirometric parameters were less notable. This applied even when stratified by the magnitude of FEV1 and DLCO reduction at baseline.
conclusionSignificant lung function impairment should raise alert of chest HRCT abnormality and sputum culture positive for Pseudomonas aeruginosa, in patients with predominantly mild to moderate steady-state bronchiectasis. Acute exacerbations elicited reductions in FVC and FEV1. Changes of other spirometric parameters were less significant during exacerbations.
trial registrationClinicalTrials.gov NCT01761214.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.